Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioretina: WJ-MSCs and rEMS for Retinitis Pigmentosa
NCT05800301Phase 3Completed
- Sponsor
- Ankara Üniversitesi Teknokent
- Start
- Jan 2019
- Primary completion
- Dec 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of wharton's jelly mesenchymal stromal cells in retinitis pigmentosa (RP), sponsored by Ankara Üniversitesi Teknokent. Started Jan 2019; status: completed.
02
Drugs
wharton's jelly mesenchymal stromal cells
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NCT05800301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05800301.